Compare Stocks: APR, BRNS, GWP, and SER

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APR Auto Prop Reit		C$0.00	C$0.00 ▼ C$0.00	N/A	N/A	N/A	47,025 shs
BRNS Barinthus Biotherapeutics	$0.74 -2.5%	$0.63	$0.51 ▼ $1.83	$30.23M	-0.37	58,092 shs	376,146 shs
SER Serina Therapeutics	$2.50 -8.4%	$2.33	$1.22 ▼ $5.83	$63.50M	1.18	1.70 million shs	42,265 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BRNS Barinthus Biotherapeutics	0.00%	+8.90%	+26.71%	+4.83%	-38.79%
SER Serina Therapeutics	0.00%	+12.81%	+13.75%	+54.24%	+272,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APR Auto Prop Reit		C$0.00	C$0.00 ▼ C$0.00	N/A	N/A	N/A	47,025 shs
BRNS Barinthus Biotherapeutics	$0.74 -2.5%	$0.63	$0.51 ▼ $1.83	$30.23M	-0.37	58,092 shs	376,146 shs
SER Serina Therapeutics	$2.50 -8.4%	$2.33	$1.22 ▼ $5.83	$63.50M	1.18	1.70 million shs	42,265 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BRNS Barinthus Biotherapeutics	0.00%	+8.90%	+26.71%	+4.83%	-38.79%
SER Serina Therapeutics	0.00%	+12.81%	+13.75%	+54.24%	+272,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APR Auto Prop Reit	2.67	Moderate Buy	N/A	N/A
BRNS Barinthus Biotherapeutics	2.00	Hold	$4.00	440.47% Upside
SER Serina Therapeutics	3.00	Buy	$8.00	220.00% Upside

Current Analyst Ratings Breakdown

Latest APR, BRNS, GWP, and SER Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2026	BRNS Barinthus Biotherapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
8/25/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/21/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/1/2026	SER Serina Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$8.00
7/1/2026	SER Serina Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$8.00
6/15/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APR Auto Prop Reit	N/A	N/A	N/A	N/A	N/A	N/A
BRNS Barinthus Biotherapeutics	$14.97M	2.02	N/A	N/A	$1.82 per share	0.41
SER Serina Therapeutics	$130K	488.46	N/A	N/A	($0.46) per share	-5.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APR Auto Prop Reit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BRNS Barinthus Biotherapeutics	-$66.43M	-$1.03	N/A	N/A	N/A	N/A	-59.15%	-43.80%	11/6/2026 (Estimated)
SER Serina Therapeutics	-$19.18M	N/A	N/A	N/A	N/A	N/A	-416.40%	-132.69%	N/A

Latest APR, BRNS, GWP, and SER Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2026	Q2 2026	SER Serina Therapeutics	N/A	-$0.55	N/A	-$0.55	N/A	N/A
8/7/2026	Q2 2026	BRNS Barinthus Biotherapeutics	-$0.28	-$0.26	+$0.02	-$0.26	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APR Auto Prop Reit	N/A	N/A	N/A	N/A	N/A
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	N/A
SER Serina Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APR Auto Prop Reit	N/A	N/A	N/A
BRNS Barinthus Biotherapeutics	N/A	5.54	5.54
SER Serina Therapeutics	0.16	6.65	6.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APR Auto Prop Reit	N/A
BRNS Barinthus Biotherapeutics	25.20%
SER Serina Therapeutics	12.50%

Insider Ownership

Company	Insider Ownership
APR Auto Prop Reit	N/A
BRNS Barinthus Biotherapeutics	8.50%
SER Serina Therapeutics	17.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APR Auto Prop Reit	N/A	N/A	N/A	Not Optionable
BRNS Barinthus Biotherapeutics	107	40.85 million	37.38 million	N/A
SER Serina Therapeutics	N/A	25.40 million	20.90 million	N/A

APR, BRNS, GWP, and SER Headlines

Recent News About These Companies

Analysts Are Bullish on These Healthcare Stocks: Tvardi Therapeutics (TVRD), GE Healthcare Technologies Inc (GEHC)

August 21, 2026 | theglobeandmail.com

Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 13, 2026 | globenewswire.com

Serina Therapeutics, Inc.: Serina Therapeutics Appoints Farrell Simon to its Board of Directors

July 24, 2026 | finanznachrichten.de

Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

July 24, 2026 | globenewswire.com

Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s Disease

July 23, 2026 | markets.businessinsider.com

Serina Therapeutics Amends CEO Employment and Compensation Terms

July 23, 2026 | tipranks.com

Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson's Disease

July 23, 2026 | globenewswire.com

Serina Therapeutics Adds Industry Veteran to Board

July 22, 2026 | tipranks.com

Serina Therapeutics Appoints Farrell Simon to its Board of Directors

July 22, 2026 | globenewswire.com

Serina concludes sentinel dosing in Phase Ib trial’s cohort 1

July 13, 2026 | msn.com

Serina Therapeutics Inc SER

July 11, 2026 | morningstar.comM

Serina Therapeutics, Inc.: Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

July 10, 2026 | finanznachrichten.de

Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease

July 9, 2026 | markets.businessinsider.com

Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

July 9, 2026 | globenewswire.com

Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program

June 30, 2026 | globenewswire.com

Serina Therapeutics Shareholders Approve Expanded Equity and Governance

June 24, 2026 | tipranks.com

Serina Therapeutics (NYSEAMERICAN:SER) Director Acquires $17,700.00 in Stock

May 27, 2026 | insidertrades.com

Serina Therapeutics (NYSEAMERICAN:SER) Director Acquires $20,101.95 in Stock

May 23, 2026 | insidertrades.com

Insider-Backed PIPE Deal May Dilute Serina Therapeutics Shareholders and Heighten Governance Risks

May 16, 2026 | tipranks.com

Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

May 14, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

APR, BRNS, GWP, and SER Company Descriptions

Auto Prop Reit TSE:APR

Automotive Properties REIT is an unincorporated, open-ended real estate investment trust focused on owning and acquiring primarily income-producing automotive dealership properties located in Canada. The REIT's portfolio currently consists of 64 income-producing commercial properties and one development property, representing approximately 2.5 million square feet of gross leasable area, in metropolitan markets across British Columbia, Alberta, Saskatchewan, Manitoba, Ontario and Québec. Automotive Properties REIT is the only public vehicle in Canada focused on consolidating automotive dealership real estate properties.

Barinthus Biotherapeutics NASDAQ:BRNS

$0.74 -0.02 (-2.49%)

Closing price 04:00 PM Eastern

Extended Trading

$0.73 -0.01 (-1.36%)

As of 05:27 PM Eastern

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Serina Therapeutics NYSEAMERICAN:SER

$2.50 -0.23 (-8.42%)

Closing price 04:10 PM Eastern

Extended Trading

$2.59 +0.09 (+3.76%)

As of 05:12 PM Eastern

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APR, BRNS, GWP, and SER Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APR, BRNS, GWP, and SER Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APR, BRNS, GWP, and SER Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APR, BRNS, GWP, and SER Company Descriptions

Auto Prop Reit TSE:APR

Barinthus Biotherapeutics NASDAQ:BRNS

Serina Therapeutics NYSEAMERICAN:SER

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APR, BRNS, GWP, and SER Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APR, BRNS, GWP, and SER Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APR, BRNS, GWP, and SER Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APR, BRNS, GWP, and SER Company Descriptions

Auto Prop Reit TSE:APR

Barinthus Biotherapeutics NASDAQ:BRNS

Serina Therapeutics NYSEAMERICAN:SER

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools